FHL2 Silencing Reduces Wnt Signaling and Osteosarcoma Tumorigenesis In Vitro and In Vivo

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Brun, Julia ^a,b   Dieudonné, François Xavier ^a,b   Marty, Caroline ^a,b   Müller, Judith ^c   Schüle, Roland ^c   Patiño García, Ana ^d   Lecanda, Fernando ^d   Fromigué, Olivia ^a,b   Marie, Pierre J ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; FOUR AND A HALF LIM DOMAIN PROTEIN 2; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; WNT10B PROTEIN; WNT5A PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; FOUR AND A HALF LIM DOMAIN PROTEIN 2 GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MIGRATION INHIBITION; MOUSE; NONHUMAN; ONCOGENE; OSTEOSARCOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RECURRENT CANCER; TISSUE MICROARRAY; TUMOR XENOGRAFT; WESTERN BLOTTING; WNT SIGNALING PATHWAY;

ANIMALS; APOPTOSIS; BETA CATENIN; BONE NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; LIM-HOMEODOMAIN PROTEINS; LUNG NEOPLASMS; MICE; MOLECULAR TARGETED THERAPY; MUSCLE PROTEINS; NEOPLASM INVASIVENESS; OSTEOSARCOMA; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; WNT PROTEINS;

EID: 84873850148     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055034     Document Type: Article

References (54)

1. Himelstein BP, (1998) Osteosarcoma and other bone cancers. Curr Opin Oncol 10: 326-333.
2. Bruland OS, Hoifodt H, Saeter G, Smeland S, Fodstad O, (2005) Hematogenous micrometastases in osteosarcoma patients. Clin Cancer Res 11: 4666-4673.
3. Nusse R, (2005) Wnt signaling in disease and in development. Cell Res 15: 28-32.
4. Bodine PV, Komm BS, (2006) Wnt signaling and osteoblastogenesis. Rev Endocr Metab Disord 7: 33-39.
5. Bodine PV, (2008) Wnt signaling control of bone cell apoptosis. Cell Res 18: 248-253.
6. Gaur T, Lengner CJ, Hovhannisyan H, Bhat RA, Bodine PV, et al. (2005) Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem 280: 33132-33140.
7. McQueen P, Ghaffar S, Guo Y, Rubin EM, Zi X, et al. (2011) The Wnt signaling pathway: implications for therapy in osteosarcoma. Expert Rev Anticancer Ther 11: 1223-1232.
8. Kansara M, Tsang M, Kodjabachian L, Sims NA, Trivett MK, et al. (2009) Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest 119: 837-851.
9. Haydon RC, Deyrup A, Ishikawa A, Heck R, Jiang W, et al. (2002) Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma. Int J Cancer 102: 338-342.
10. Entz-Werle N, Lavaux T, Metzger N, Stoetzel C, Lasthaus C, et al. (2007) Involvement of MET/TWIST/APC combination or the potential role of ossification factors in pediatric high-grade osteosarcoma oncogenesis. Neoplasia 9: 678-688.
11. Dieudonné FX, Marion A, Haÿ E, Marie PJ, Modrowski D, (2010) High Wnt signaling represses the proapoptotic proteoglycan syndecan-2 in osteosarcoma cells. Cancer Res 70: 5399-5408.
12. Johannessen M, Moller S, Hansen T, Moens U, Van Ghelue M, (2006) The multifunctional roles of the four-and-a-half-LIM only protein FHL2. Cell Mol Life Sci 63: 268-284.
13. Kleiber K, Strebhardt K, Martin BT, (2007) The biological relevance of FHL2 in tumour cells and its role as a putative cancer target. Anticancer Res 27: 55-61.
14. Martin B, Schneider R, Janetzky S, Waibler Z, Pandur P, et al. (2002) The LIM-only protein FHL2 interacts with beta-catenin and promotes differentiation of mouse myoblasts. J Cell Biol 159: 113-122.
15. Wei Y, Renard CA, Labalette C, Wu Y, Levy L, et al. (2003) Identification of the LIM protein FHL2 as a coactivator of beta-catenin. J Biol Chem 278: 5188-5194.
16. Amaar YG, Thompson GR, Linkhart TA, Chen ST, Baylink DJ, et al. (2002) Insulin-like growth factor-binding protein 5 (IGFBP-5) interacts with a four and a half LIM protein 2 (FHL2). J Biol Chem 277: 12053-12060.
17. Gunther T, Poli C, Muller JM, Catala-Lehnen P, Schinke T, et al. (2005) Fhl2 deficiency results in osteopenia due to decreased activity of osteoblasts. Embo J 24: 3049-3056.
18. Lai CF, Bai S, Uthgenannt BA, Halstead LR, McLoughlin P, et al. (2006) Four and half lim protein 2 (FHL2) stimulates osteoblast differentiation. J Bone Miner Res 21: 17-28.
19. Hamidouche Z, Haÿ E, Vaudin P, Charbord P, Schüle R, et al. (2008) FHL2 mediates dexamethasone-induced mesenchymal cell differentiation into osteoblasts by activating Wnt/beta-catenin signaling-dependent Runx2 expression. FASEB J 22: 3813-3822.
20. Khanna C, Khan J, Nguyen P, Prehn J, Caylor J, et al. (2001) Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res 61: 3750-3759.
21. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, et al. (1998) Identification of c-MYC as a target of the APC pathway. Science 281: 1509-1512.
22. Chen K, Fallen S, Abaan HO, Hayran M, Gonzalez C, et al. (2008) Wnt10b induces chemotaxis of osteosarcoma and correlates with reduced survival. Pediatr Blood Cancer 51: 349-355.
23. Enomoto M, Hayakawa S, Itsukushima S, Ren DY, Matsuo M, et al. (2009) Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling. Oncogene 28: 3197-3208.
24. Lu BJ, Wang YQ, Wei XJ, Rong LQ, Wei D, et al. (2012) Expression of WNT-5a and ROR2 correlates with disease severity in osteosarcoma. Mol Med Report 5: 1033-1036.
25. Essers MA, de Vries-Smits LM, Barker N, Polderman PE, Burgering BM, et al. (2005) Functional interaction between beta-catenin and FOXO in oxidative stress signaling. Science 308: 1181-1184.
26. Jaffe N, (2009) Osteosarcoma: review of the past, impact on the future. The American experience. Cancer Treat Res 152: 239-262.
27. Khanna C, Prehn J, Yeung C, Caylor J, Tsokos M, et al. (2000) An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin Exp Metastasis 18: 261-271.
28. Kansara M, Thomas DM, (2007) Molecular pathogenesis of osteosarcoma. DNA Cell Biol 26: 1-18.
29. Martin BT, Kleiber K, Wixler V, Raab M, Zimmer B, et al. (2007) FHL2 regulates cell cycle-dependent and doxorubicin-induced p21Cip1/Waf1 expression in breast cancer cells. Cell Cycle 6: 1779-1788.
30. Li M, Wang J, Ng SS, Chan CY, Chen AC, et al. (2008) The four-and-a-half-LIM protein 2 (FHL2) is overexpressed in gliomas and associated with oncogenic activities. Glia 56: 1328-1338.
31. Tanahashi H, Tabira T, (2000) Alzheimer's disease-associated presenilin 2 interacts with DRAL, an LIM-domain protein. Hum Mol Genet 9: 2281-2289.
32. Labalette C, Nouet Y, Levillayer F, Colnot S, Chen J, et al. (2010) Deficiency of the LIM-only protein FHL2 reduces intestinal tumorigenesis in Apc mutant mice. PLoS One 5: e10371.
33. Wang J, Yang Y, Xia HH, Gu Q, Lin MC, et al. (2007) Suppression of FHL2 expression induces cell differentiation and inhibits gastric and colon carcinogenesis. Gastroenterology 132: 1066-1076.
34. Kinoshita M, Nakagawa T, Shimizu A, Katsuoka Y, (2005) Differently regulated androgen receptor transcriptional complex in prostate cancer compared with normal prostate. Int J Urol 12: 390-397.
35. Muller JM, Isele U, Metzger E, Rempel A, Moser M, et al. (2000) FHL2, a novel tissue-specific coactivator of the androgen receptor. EMBO J 19: 359-369.
36. Morlon A, Sassone-Corsi P, (2003) The LIM-only protein FHL2 is a serum-inducible transcriptional coactivator of AP-1. Proc Natl Acad Sci U S A 100: 3977-3982.
37. Purcell NH, Darwis D, Bueno OF, Muller JM, Schüle R, et al. (2004) Extracellular signal-regulated kinase 2 interacts with and is negatively regulated by the LIM-only protein FHL2 in cardiomyocytes. Mol Cell Biol 24: 1081-1095.
38. Park J, Will C, Martin B, Gullotti L, Friedrichs N, et al. (2008) Deficiency in the LIM-only protein FHL2 impairs assembly of extracellular matrix proteins. FASEB J 22: 2508-2520.
39. Ding L, Wang Z, Yan J, Yang X, Liu A, et al. (2009) Human four-and-a-half LIM family members suppress tumor cell growth through a TGF-beta-like signaling pathway. J Clin Invest 119: 349-361.
40. Labalette C, Nouet Y, Sobczak-Thepot J, Armengol C, Levillayer F, et al. (2008) The LIM-only protein FHL2 regulates cyclin D1 expression and cell proliferation. J Biol Chem 283: 15201-15208.
41. Labalette C, Renard CA, Neuveut C, Buendia MA, Wei Y, (2004) Interaction and functional cooperation between the LIM protein FHL2, CBP/p300, and beta-catenin. Mol Cell Biol 24: 10689-10702.
42. Scholl FA, McLoughlin P, Ehler E, de Giovanni C, Schafer BW, (2000) DRAL is a p53-responsive gene whose four and a half LIM domain protein product induces apoptosis. J Cell Biol 151: 495-506.
43. Ng CF, Ng PK, Lui VW, Li J, Chan JY, et al. (2011) FHL2 exhibits anti-proliferative and anti-apoptotic activities in liver cancer cells. Cancer Lett 304: 97-106.
44. Almeida M, Han L, Bellido T, Manolagas SC, Kousteni S, (2005) Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by beta-catenin-dependent and-independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT. J Biol Chem 280: 41342-41351.
45. Yang Y, Hou H, Haller EM, Nicosia SV, Bai W, (2005) Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation. EMBO J 24: 1021-1032.
46. Ambrogini E, Almeida M, Martin-Millan M, Paik JH, Depinho RA, et al. (2010) FoxO-mediated defense against oxidative stress in osteoblasts is indispensable for skeletal homeostasis in mice. Cell Metab 11: 136-146.
47. Zhang W, Wang J, Zou B, Sardet C, Li J, et al. (2011) Four and a half LIM protein 2 (FHL2) negatively regulates the transcription of E-cadherin through interaction with Snail1. Eur J Cancer 47: 121-130.
48. Gullotti L, Czerwitzki J, Kirfel J, Propping P, Rahner N, et al. (2011) FHL2 expression in peritumoural fibroblasts correlates with lymphatic metastasis in sporadic but not in HNPCC-associated colon cancer. Lab Invest 91: 1695-1705.
49. Kikuchi A, Yamamoto H, Sato A, Matsumoto S, (2011) Wnt5a: its signalling, functions and implication in diseases. Acta Physiol (Oxf) 204: 17-33.
50. Wend P, Wend K, Krum SA, Miranda-Carboni GA, (2012) The role of WNT10B in physiology and disease. Acta Physiol (Oxf) 204: 34-51.
51. Wixler V, Geerts D, Laplantine E, Westhoff D, Smyth N, et al. (2000) The LIM-only protein DRAL/FHL2 binds to the cytoplasmic domain of several alpha and beta integrin chains and is recruited to adhesion complexes. J Biol Chem 275: 33669-33678.
52. Fromigué O, Hamidouche Z, Marie PJ, (2008) Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion. J Biol Chem 283: 30549-30556.
53. Fromigué O, Haÿ E, Modrowski D, Bouvet S, Jacquel A, et al. (2006) RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation. Cell Death Differ 13: 1845-1856.
54. Müller JM, Metzger E, Greschik H, Bosserhoff AK, Mercep, et al, (2012) EMBO J. The transcriptional coactivator FHL2 transmits Rho signals from the cell membrane into the nucleus. EMBO J 21: 736-748.